CCDC112 inhibitors encompass a diverse array of chemical compounds that indirectly contribute to the inhibition of this protein's functional activity by modulating various cellular processes and signaling pathways. Agents that disrupt the Golgi apparatus, such as one that interferes with vesicle-mediated transport, can affect the post-translational modification and proper localization of CCDC112, resulting in its functional impairment. Similarly, ionophores that perturb intracellular ion gradients can compromise the correct folding and trafficking of CCDC112, leading to inhibition. Inhibition of the GTPase activity of dynamin, which is crucial for vesicle scission from the Golgi, and destabilization of microtubules both impede intracellular transport mechanisms, crucial for CCDC112 localization and function. Disruption of the actin cytoskeleton, which is essential for the trafficking of some proteins, can also inhibit the movement and, consequently, the function of CCDC112.
Furthermore, inhibition of tyrosine kinase activity can block critical phosphorylation events that activate CCDC112, while alterations in the phosphorylation state of proteins through the inhibition of protein phosphatases may also affect CCDC112 function. The alteration of intracellular signaling pathways that regulate vesicle trafficking, such as those influenced by phosphoinositide 3-kinase inhibitors, may disrupt CCDC112 localization and function. Agents that modulate the pH of intracellular vesicles can interfere with the degradation pathways of proteins, including CCDC112, leading to its functional inhibition. Compounds that inhibit N-linked glycosylation can result in the production of misfolded proteins that are typically targeted for degradation, thus inhibiting CCDC112. Proteasome inhibitors prevent the degradation of ubiquitinated proteins, potentially leading to the accumulation of dysfunctional CCDC112.Lastly, transcription factor inhibition can downregulate the expression of many genes, potentially including those critical for CCDC112 synthesis, leading to decreased protein levels and subsequent inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
This compound disrupts the structure and function of the Golgi apparatus, which can impact the post-translational modification and proper localization of CCDC112, leading to its functional inhibition. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
As an ionophore that alters intracellular sodium and hydrogen levels, Monensin A can interfere with pH homeostasis and ion gradients, which are critical for the correct folding and trafficking of CCDC112, resulting in its inhibition. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
This small molecule inhibitor of the GTPase activity of dynamin interferes with vesicle scission from the Golgi, potentially preventing the proper vesicular transport of CCDC112, thus inhibiting its function. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
By destabilizing microtubules, Nocodazole can impede intracellular transport mechanisms essential for the localization and function of CCDC112, leading to its inhibition. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $145.00 $442.00 | 64 | |
This compound disrupts actin polymerization, and given the dependence of trafficking of some proteins on the actin cytoskeleton, it may impede the intracellular movement of CCDC112, thereby inhibiting its function. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
As a tyrosine kinase inhibitor, Genistein can block phosphorylation events that are critical for the activation and function of CCDC112, resulting in inhibition. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
This inhibitor of protein phosphatases 1 and 2A can alter the phosphorylation state of proteins, potentially affecting CCDC112 function if it relies on proper phosphorylation for its activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
By inhibiting phosphoinositide 3-kinases, Wortmannin can alter intracellular signaling and vesicle trafficking, which may be critical for CCDC112 localization and function, leading to its inhibition. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
As an agent that raises the pH of acidic vesicles, Chloroquine can affect the maturation of endosomes and lysosomes, potentially disrupting the degradation pathway of CCDC112, leading to its accumulation and functional inhibition. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
This compound inhibits N-linked glycosylation, which can be essential for the stability and function of CCDC112. The resulting misfolded proteins are typically targeted for degradation, leading to inhibition of CCDC112. |